Clinical trials: MI(Myocardial Infarction)
Myocardial Infarction
Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
This is a multicenter, randomized, double-blind, active-controlled, dose-titrating phase 2 study to evaluate the safety and efficacy of firibastat administered orally BID (2 daily doses) versus ramipril administered orally BID…
- Trial name
- QUORUM (NCT03715998)
- Testing
- Ramipril, Firibastat
- Where
- 7 sites in France, Germany and 5 more
- Volunteers
- 295 people
- Sponsor
- Quantum Genomics SA
Post MI Left Ventricular Dysfunction
IdeNtifying High riSk Patients Post Myocardial Infarction With REduced Left Ventricular Function Using External Loop Recorders (INSPIRE-ELR Study)
The purpose of the INSPIRE-ELR study is to characterize arrhythmias in post MI low EF (≤35%) patients in the acute phase (at discharge from hospital after index MI) and chronic phase (at 8-10 weeks after index MI) and to…
- Trial name
- INSPIRE-ELR (NCT01995552)
- Testing
- External Loop Recorder
- Where
- India
- Volunteers
- 250 people
- Sponsor
- Medtronic BRC
Myocardial Infarction, Comorbidity
Web-Enhanced Guideline Implementation for Post MI CBOC Patients
To assist busy primary care clinicians in VA Community Based Outpatient Clinics (CBOCs) in managing complex patients by providing a single, interactive, and personalized source of information regarding applicable guidelines for…
- Trial name
- VA MI Plus (NCT00126750)
- Testing
- VA MI Plus Interactive
- Where
- 41 sites in United States, Puerto Rico
- Volunteers
- 847 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Cardiogenic Shock, Acute Myocardial Infarction
National Cardiogenic Shock Initiative
This study evaluates the use of early mechanical circulatory support in patients presenting with acute myocardial infarction and cardiogenic shock.
- Conditions
- Cardiogenic Shock, Acute Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
- Trial name
- NCSI (NCT03677180)
- Where
- 75 sites in United States
- Volunteers
- 406 people
- Sponsor
- Henry Ford Health System
Acute Myocardial Infarction
COOL AMI EU Pivotal Trial to Assess Cooling as an Adjunctive Therapy to PCI In Patients With Acute MI (Phase A)
The objective of this trial is to evaluate the safety and effectiveness of therapeutic hypothermia, using the ZOLL Proteus IVTM System, as an adjunctive therapy for patients presenting with acute anterior myocardial infarction…
- Trial name
- NCT03173313
- Testing
- Intravascular permissive hypothermia as an adjunct to PCI
- Where
- Slovenia
- Volunteers
- 111 people
- Sponsor
- ZOLL Circulation, Inc., USA
Heart Disease
Vet-Harts Pilot Intervention for Veterans With Coronary Heart Disease
The purpose of this research study is to survey patients to learn about their beliefs and behaviors related to the management of heart disease and to discuss options for making healthy lifestyle changes.
- Trial name
- VHPI (NCT01566214)
- Testing
- Motivational Interview
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- VA Office of Research and Development
Coronary Disease
Effects of Atorvastatin on Myonecrosis
This study is designed as a prospective, randomized, placebo-controlled, double-blind analysis of atorvastatin 80 mg versus placebo administered on average 4 hours prior to percutaneous coronary intervention [PCI] (at least 2…
- Trial name
- NCT00344019
- Testing
- Atorvastatin 80mg, Screening
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Beth Israel Deaconess Medical Center
Left Ventricular Dysfunction Post Myocardial Infarction
Patient's Management Receiving Eplerenone Therapy
On a population of patients followed by an office-based cardiologist and treated with eplerenone, the objectives of the survey are: To describe the characteristics of the population treated.
- Trial name
- PERGAME (NCT01440049)
- Testing
- Prospective Observational
- Volunteers
- 160 people
- Sponsor
- Pfizer
ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
Ticagrelor Administered as Standard Tablet or Orodispersible Formulation
Randomized clinical study evaluating superiority in platelet inhibition after administration of Ticagrelor 180 mg loading dose as an orodispersible formulation versus traditional coated tablets in patients admitted for ST…
- Trial name
- TASTER (NCT03822377)
- Testing
- Ticagrelor orodispersible tablets, Ticagrelor standard tablets
- Where
- Italy
- Volunteers
- 130 people
- Sponsor
- Azienda Ospedaliero Universitaria di Sassari
Coronary Artery Disease
Resolute Integrity US Extended Length Sub-Study(RI US XL)
Prospective, multi-center, non-randomized, single-arm, open-label study to assess the safety and efficacy of the Resolute Integrity Stent for the treatment of de novo lesions in native coronary arteries with a reference vessel…
- Trial name
- RI-US XL (NCT01913600)
- Testing
- Resolute Integrity Stent
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Medtronic Vascular
Cost Sharing, Acute Coronary Syndrome
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes.
- Trial name
- ARTEMIS (NCT02406677)
- Testing
- Study voucher card
- Where
- 272 sites in United States, Puerto Rico
- Volunteers
- 11,001 people
- Sponsor
- AstraZeneca
Coronary Artery Disease, Coronary Stenosis
ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI)
The objective of this prospective, single-blind clinical investigation is to demonstrate the superiority of an Optical Coherence Tomography (OCT)-guided stent implantation strategy as compared to an angiography-guided stent…
- Conditions
- Coronary Artery Disease, Coronary Stenosis, Atherosclerosis, STEMI
- Trial name
- NCT03507777
- Testing
- Coronary PCI guided by OCT, Coronary PCI guided by Angiography
- Where
- 90 sites in United States, Australia and 18 more
- Volunteers
- 2,487 people
- Sponsor
- Abbott Medical Devices
Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR)
The Effect of IV Cangrelor and Oral Ticagrelor Study
Major heart attacks are caused by a number of factors, the two major of which are furring up of a coronary artery with atheroma and then sudden clot formation on this area leading to a blockage and interruption of blood flow.
- Conditions
- Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR), Microvascular Obstruction (MVO), ST-segment Elevation Myocardial Infarction (STEMI)
- Trial name
- NCT02733341
- Testing
- Cangrelor, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Acute Coronary Syndrome
Evolocumab in Patients With Acute MI
Vascular and myocardial inflammation are significantly increased in Acute Coronary Syndrome (ACS) patients, are closely correlated to LDL-C levels, and are associated with these adverse consequences in the post-ACS patient…
- Trial name
- EVACS II (NCT04082442)
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Johns Hopkins University
Heart Failure
The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
Prior to reperfusion therapy, the major therapeutic breakthrough in myocardial infarction was the demonstration that ACE inhibitors or ARBs, given to prevent adverse "remodelling" (progressive dilatation and decline in systolic…
- Trial name
- RECOVER-LV (NCT03552575)
- Testing
- sacubitril/valsartan, Valsartan
- Where
- 2 sites in United Kingdom
- Volunteers
- 93 people
- Sponsor
- NHS Greater Glasgow and Clyde
Coronary Artery Disease
The Medtronic RESOLUTE US Clinical Trial
The objective of the study is to assess the safety and effectiveness of the Resolute Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter…
- Trial name
- R-US (NCT00726453)
- Testing
- Resolute Zotarolimus-Eluting Coronary Stent
- Where
- United States
- Volunteers
- 1,516 people
- Sponsor
- Medtronic Vascular
Myocardial Infarction
Mental Stress and Myocardial Ischemia After MI: Sex Differences, Mechanisms and Prognosis
The purpose of this study is to look at the link between emotional stress and heart disease in men and women. Taking part in this study involves one clinic visit, one week of at home monitoring, and follow up phone calls every 6…
- Trial name
- MIMS3 (NCT04123197)
- Testing
- Stress Challenge
- Where
- 3 sites in United States
- Volunteers
- 306 people
- Sponsor
- Emory University
Cardiovascular Diseases, Heart Diseases
Occluded Artery Trial (OAT)
The purpose of this study is to determine whether opening an occluded infarcted artery 3-28 days after an acute myocardial infarction in high-risk asymptomatic patients reduces the composite endpoint of mortality, recurrent…
- Conditions
- Cardiovascular Diseases, Heart Diseases, Myocardial Infarction, Heart Failure, Congestive
- Trial name
- OAT (NCT00004562)
- Testing
- Beta adrenergic blockers, Platelet inhibitors, PTCA and stents
- Where
- United States
- Volunteers
- 2,201 people
- Sponsor
- NYU Langone Health
Prevention & Control
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
The primary objectives of this study are: To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction…
- Trial name
- COMPASS (NCT01776424)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Pantoprazole
- Where
- 565 sites in United States, Argentina and 31 more
- Volunteers
- 27,395 people
- Sponsor
- Bayer
Myocardial Infarction
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
This is a study in adults who had a heart attack (myocardial infarction). The purpose of this study is to find out whether a medicine called empagliflozin helps to lower the chances of having to go to the hospital for heart…
- Trial name
- NCT04509674
- Testing
- Empagliflozin
- Where
- 439 sites in United States, Argentina and 20 more
- Volunteers
- 6,522 people
- Sponsor
- Boehringer Ingelheim